Nuvation Bio Inc. Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, 12 Months or Longer
Nuvation Bio Inc. (NUVB) had Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, 12 Months or Longer of $0 as of 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Notes › Debt and Equity Securities › Debt Securities, Available-for-Sale, Unrealized Loss Position
us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger · last filed 2026-08-06
- 2026-06-30: Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, 12 Months or Longer $0.00.
- 2026-03-31: Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, 12 Months or Longer $0.00.
- 2025-12-31: Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, 12 Months or Longer $0.00.
- 2025-09-30: Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, 12 Months or Longer $4.01M.
| Period end | Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, 12 Months or Longer |
|---|---|
| 2026-06-30 | $0.00 10-Q · filed 2026-08-06 |
| 2026-03-31 | $0.00 10-Q · filed 2026-05-04 |
| 2025-12-31 | $0.00 10-Q · filed 2026-08-06 |
| 2025-09-30 | $4.01M 10-Q · filed 2025-11-03 |
| 2025-06-30 | $0.00 10-Q · filed 2025-08-07 |
| 2025-03-31 | $5.93M 10-Q · filed 2025-05-07 |
| 2024-12-31 | $55.01M 10-K · filed 2026-03-02 |
| 2024-09-30 | $89.73M 10-Q · filed 2024-11-06 |
| 2024-06-30 | $127.27M 10-Q · filed 2024-08-05 |
| 2024-03-31 | $29.71M 10-Q · filed 2024-05-14 |
| 2023-12-31 | $51.24M 10-K · filed 2025-03-06 |
| 2023-09-30 | $90.01M 10-Q · filed 2023-11-02 |
| 2023-06-30 | $83.74M 10-Q · filed 2023-08-03 |
| 2023-03-31 | $123.65M 10-Q · filed 2023-05-04 |
| 2022-12-31 | $212.81M 10-K · filed 2024-02-29 |
| 2022-09-30 | $122.07M 10-Q · filed 2022-11-03 |
| 2022-06-30 | $30.34M 10-Q · filed 2022-08-04 |
| 2022-03-31 | $16.63M 10-Q · filed 2022-05-09 |
| 2021-12-31 | $0.00 10-K · filed 2023-03-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| UroGen Pharma Ltd. (URGN) | $2.015B | -18.42 | |
| Biohaven Ltd. (BHVN) | United States | $1.990B | -3.83 |
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| AGIOS PHARMACEUTICALS, INC. (AGIO) | United States | $1.962B | -5.38 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| Sarepta Therapeutics, Inc. (SRPT) | United States | $1.941B | -13.89 |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B |